PDA Points to Consider: Technical Product Lifecycle Management. Pharmaceutical Quality System Effectiveness for Managing Post-approval Changes

Reference

1. 1.↵
   Quality Guideline Q10: Pharmaceutical Quality System; International Conference on Harmonisation: Geneva, Switzerland, 2008 [http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html (accessed August 28, 2016)].
2. 2.↵
   PDA Points to Consider: Technical Product Lifecycle Management: Communication and Knowledge Exchange between Marketing Authorization Holders and Health Authorities. PDA J. Pharm. Sci. Technol. (accepted article January 2017) [journal.pda.org (accessed January 23, 2017)].
3. 3.↵
   Quality Guideline Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management, concept paper and business plan; ICH: Geneva, 2014.
4. Concept paper: [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q12/Q12_Final_Concept_Paper_July_2014.pdf (accessed December 2016)].
5. Business plan: [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q12/Q12_Final_Buisness_Plan_July_2014.pdf (accessed December 2016)].
6. 4.↵
   White Paper: FDA Pharmaceutical Quality Oversight, One Quality Voice; Office of Pharmaceutical Quality, U.S. Food and Drug Administration, U.S. Government Printing Office: Washington, DC, 2015 [http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM442666.pdf (accessed January 6, 2017)].
7. 5.↵
   Final Report on Pharmaceutical cGMPs for the 21st Century—A Risk Based Approach; U.S. Food and Drug Administration, September, 2004 [http://www.fda.gov/downloads/drugs/developmentapprovalprocess/manufacturing/questionsandanswersoncurrentgoodmanufacturingpracticescgmpfordrugs/ucm176374.pdf (accessed January 23, 2017].